CONSUN PHARMA (01681) · Company profile · Eqvero

CONSUN PHARMA

01681HKEX

Unit: CNY	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	3.42 bn CNY	2.97 bn CNY	2.59 bn CNY	2.34 bn CNY	2.04 bn CNY
Cost of revenue	683.65 m CNY	661.14 m CNY	590.35 m CNY	500.38 m CNY	444.34 m CNY
Research and development expense	151.84 m CNY	97.54 m CNY	108.54 m CNY	117.54 m CNY	102.16 m CNY
Selling, general and administrative expense	1.52 bn CNY	1.29 bn CNY	1.17 bn CNY	1.09 bn CNY	900 m CNY
Operating profit after depreciation	1.15 bn CNY	974.99 m CNY	825.92 m CNY	715.41 m CNY	660.18 m CNY
Operating profit before depreciation	1.22 bn CNY	1.04 bn CNY	904.01 m CNY	791.76 m CNY	733.17 m CNY
EBIT	1.15 bn CNY	974.99 m CNY	825.92 m CNY	715.41 m CNY	660.18 m CNY
EBITDA	1.22 bn CNY	1.04 bn CNY	904.01 m CNY	791.76 m CNY	733.17 m CNY
Interest expense	4.36 m CNY	24.89 m CNY	21.26 m CNY	10.93 m CNY	12.91 m CNY
Profit before tax	1.2 bn CNY	1.02 bn CNY	863.7 m CNY	746.39 m CNY	695.86 m CNY
Income tax expense	107.29 m CNY	102.73 m CNY	77.15 m CNY	62.7 m CNY	108.74 m CNY
Income before extraordinary items	1.08 bn CNY	910.46 m CNY	784.53 m CNY	682.91 m CNY	590.17 m CNY
Common dividends	549.51 m CNY	465.13 m CNY	330.19 m CNY	208.07 m CNY	195.57 m CNY
Total dividends	549.51 m CNY	465.13 m CNY	330.19 m CNY	208.07 m CNY	195.57 m CNY

Quotes are end-of-day data. Content is for research purposes and is not investment advice.